[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360314-105":59,"doc-detail-360314-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pathogenic-germline-palb2-and-rad50-variants-in-patients-with-relapsed-ewing-sarcoma","Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma","","Approximately 10% of patients with Ewing sarcoma (EwS) carry pathogenic germline variants. The report presents two clinical cases: a late EwS relapse harboring a novel PALB2 germline pathogenic variant, with demonstrated effects on homologous recombination and discussion of breast cancer risk. A second case describes a RAD50 germline variant in a patient with rare prostate primary EwS, later concurrent relapsed EwS and therapy-related acute myeloid leukemia (tAML) with two KMT2A translocations. Interpreting rare germline variants is important for understanding cancer behavior, treatment response, and associated toxicities.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pathogenic-germline-palb2-and-rad50-variants-in-patients-with-relapsed-ewing-sarcoma/360314/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pathogenic-germline-palb2-and-rad50-variants-in-patients-with-relapsed-ewing-sarcoma/360314.png","ImageObject",300,407,{"name":92,"@type":93},"Stanley","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What percentage of Ewing sarcoma patients are reported to have pathogenic germline variants?","Question",{"text":112,"@type":113},"Approximately 10% of patients with Ewing sarcoma have pathogenic germline variants.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What germline variants are described in the two cases?",{"text":117,"@type":113},"One case involves a novel PALB2 germline pathogenic variant in a patient with a late Ewing sarcoma relapse. The second case involves a pathogenic RAD50 germline variant in a patient with relapsed Ewing sarcoma and concurrent therapy-related acute myeloid leukemia (tAML).",{"name":119,"@type":110,"acceptedAnswer":120},"How does PALB2 relate to homologous recombination, according to the report?",{"text":121,"@type":113},"PALB2 is described as a protein involved in homologous recombination DNA damage repair complexes, interacting with BRCA1 and BRCA2-associated components and supporting DNA repair functions.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360314,1790748386,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},2336477405376,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Author Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Pediatr Blood Cancer. Author manuscript; available in PMC 2026 May 31. |\n| --- | --- |\n\nPublished in final edited form as:  \nPediatr Blood Cancer. 2026 March ; 73(3): e70122 . doi:10.1002/1545-5017.70122 .  \nPathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma  \nMolly Mack 1 , A. Carolina Tufino 1 , Mohd Azrin Jamalruddin2,3 , Sreya Dey 1 , Yinghong Pan4 , Elina Mukherjee 1 , Jessica D. Daley 1 , Julia Meade 1 , Mahmoud Aarabi5 , Lisa Maurer1 , James Cooper1 , Kara A. Bernstein3 , Kelly M. Bailey 1,6  \n1 University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA  \n2Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA  \n3 Department of Biochemistry and Biophysics, Penn Center for Genome Integrity, Basser Center for BRCA, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA  \n4 Department of Obstetrics and Gynecology, UPMC Magee-Women’s Hospital, Pittsburgh, Pennsylvania, USA  \n5 Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA  \n6 Department of Pediatrics, Mayo Clinic Children’s, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA  \nAbstract  \nApproximately 10% of patients with Ewing sarcoma (EwS) have pathogenic germline variants.  \nHere, we report two cases: first, a novel germline pathogenic variant in partner and localizer of BRCA2 (PALB2) in a patient with a late EwS relapse. Its impact on homologous recombination is demonstrated, and breast cancer risk is discussed. Second, we report a pathogenic germline variant in RAD50 in a patient with a rare prostate primary EwS and later concurrent relapsed EwS and therapy-related acute myeloid leukemia (tAML) with two rare KMT2Atranslocations.  \nUnderstanding rare pathogenic germline variants and the impact on cancer behavior, response to treatment and treatment-associated toxicities is important for patients.  \nKeywords  \nbreast cancer; Ewing sarcoma; partner and localizer ofBRCA2 (PALB2); RAD50 ; treatmentrelated acute myeloid leukemia (tAML)  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \nCorrespondence: Kelly M. Bailey ([Bailey.Kelly@mayo.edu](Bailey.Kelly@mayo.edu)).  \nMolly Mack and A. Carolina Tufino denote co-first author status.  \nEthics Statement  \nInformed Consent for both of the cases presented was obtained and properly documented.  \nConflicts of Interest  \nThe authors declare no conflicts of interest.  \nAuthor Manuscr ipt Author Manuscr ipt Author Manuscr ipt Author Manuscript  \nMack et al. Page 2  \n1 ∣ Introduction  \nEfforts to increase germline sequencing in patients with pediatric cancer have expanded the landscape of germline findings in patients with Ewing sarcoma (EwS) in the past ~5 years [1, 2] . Though not a cancer classically associated with cancer predisposition syndromes, it is now known that approximately 10%–15% of patients with EwS have germline pathogenic variants [1]. Many of the genes identified to date are involved in DNA damage repair ( FANCC, CHEK2, FANCA, etc.) [2, 3] . Our lab previously reported the first patient with EwS found to have a pathogenic germline variant in the BRCA1-associated RING domain 1 gene (BARD1) [4, 5]. Understanding these rare germline events is important for patients and their families.  \nHere, we report rare germline pathogenic variants, including a novel partner and localizer of BRCA2 (PALB2) variant, in a patient with relapsed EwS and a RAD50 variant in a patient with relapsed EwS and concurrent therapy-related acute myeloid leukemia (tAML) with two separate KMT2A gene fusions identified.","cbCaiua6jeSO6z4T","https://ap.wps.com/l/cbCaiua6jeSO6z4T","pdf",718561,"English","# Introduction\n## Methods and Results\n### Methods\n### Case Report\n### DR-GFP Assay","[{\"question\":\"What percentage of Ewing sarcoma patients are reported to have pathogenic germline variants?\",\"answer\":\"Approximately 10% of patients with Ewing sarcoma have pathogenic germline variants.\"},{\"question\":\"What germline variants are described in the two cases?\",\"answer\":\"One case involves a novel PALB2 germline pathogenic variant in a patient with a late Ewing sarcoma relapse. The second case involves a pathogenic RAD50 germline variant in a patient with relapsed Ewing sarcoma and concurrent therapy-related acute myeloid leukemia (tAML).\"},{\"question\":\"How does PALB2 relate to homologous recombination, according to the report?\",\"answer\":\"PALB2 is described as a protein involved in homologous recombination DNA damage repair complexes, interacting with BRCA1 and BRCA2-associated components and supporting DNA repair functions.\"}]","Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma | PDF",1790139581,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a01c4ad4cf543ac38f5ed266e1c2175.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cb0fd7283e205e54c1f4b0d07fc23b1.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f3adc2ab775b763fa5bdc37d0709bca.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/48e219de7768fab1825d68a66c7a747e.webp",980,1268]